The findings were presented on March 1 at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS ... impact on factors such as the NLRP3 inflammasome, which could ...

ZYIL1 is a novel oral small molecule NLRP3 inhibitor ... According to Rutgers researchers, the majority of people with multiple sclerosis (MS) choose oral medications to treat the chronic and ...

Diet plays a pivotal role in influencing autoimmu n e diseases like multiple sclerosis (MS), inflammatory ... inflammatory signals by inhibiting the NLRP3 inflammasome, a protein complex involved ...

which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis. Brian Hilberdink, Boehringer Ingelheim's new Head ...